VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Long Peptide Vaccine 7

Vaccine Information

Vaccine Name: Long Peptide Vaccine 7
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007498
Type: Other
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
Antigen: p53, KRAS
human TP53 (P53) gene engineering:
- Type: Recombinant protein preparation
- Description: (Quandt et al., 2018)
- Detailed Gene Information: Click Here.
KRAS gene engineering:
- Type: Recombinant protein preparation
- Description: (Quandt et al., 2018)
- Detailed Gene Information: Click Here.
Description: A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types. (NCIT_C116067).

Host Response

References

NCIT_C116067: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116067]

Quandt et al., 2018: Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schölch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018; 7(12); e1500671. [PubMed: 30524892].